Thrombopoietin

Summary

Thrombopoietin (TPO) is the primary endogenous regulator of platelet production, produced mainly by the liver. Recombinant forms were developed in the 1990s but withdrawn due to immunogenicity; however, TPO-receptor agonists (e.g., romiplostim, eltrombopag) have since replaced direct TPO use clinically. Native TPO and first-generation recombinant TPO (rhTPO, PEG-rHuMGDF) remain subjects of research. A second-generation recombinant TPO is approved in China.

Mechanism of Action

Binds and activates the thrombopoietin receptor (c-Mpl/MPL) on megakaryocyte progenitors and platelets, stimulating megakaryocyte proliferation, differentiation, and platelet production via JAK2/STAT5, PI3K/AKT, and MAPK/ERK signaling pathways.

Routes of Administration

Goals & Uses

• Aplastic anemia / bone marrow failureHematologyLow
• Platelet production stimulation prior to stem cell transplantHematology / TransplantationModerate
• Immune thrombocytopenia (ITP)HematologyModerate
• Chemotherapy-induced thrombocytopenia treatmentHematologyModerate

Contraindications

• Thrombotic disorders / hypercoagulable statesHematologicHigh
• History of TPO antibody-mediated thrombocytopeniaImmunologicHigh
• Myeloproliferative neoplasmsOncologicHigh

Adverse Effects

• Bone painMusculoskeletalUncommon
• Fever and flu-like symptomsConstitutionalUncommon
• Injection site reactionsLocalCommon
• Thrombocytosis / thrombosisHematologicUncommon
• Neutralizing anti-TPO antibodies causing thrombocytopeniaImmunologicUncommon

Drug Interactions

• Other hematopoietic growth factors (e.g., G-CSF, EPO)Low
• TPO-receptor agonists (romiplostim, eltrombopag)Moderate
• Anticoagulants (e.g., warfarin, heparin)Moderate

Population Constraints

• PregnancyReproductive SafetyRelative
• Patients with active malignancyOncologyRelative
• Pediatric patientsAgeRelative
• Renal or hepatic impairmentOrgan DysfunctionRelative

Regulatory Status

• European UnionUnapprovedNo EMA-approved recombinant TPO product. Development discontinued in Europe after PEG-rHuMGDF safety concerns.
• United StatesUnapprovedNo FDA-approved recombinant TPO product. PEG-rHuMGDF clinical trials halted due to immunogenicity. TPO-receptor agonists are the approved standard of care.
• United KingdomUnapprovedNot approved by MHRA; same situation as EU following withdrawal of early recombinant forms.

Full-length recombinant human TPO (rhTPO, e.g., Tpiao) is approved in China for chemotherapy-induced thrombocytopenia. PEG-rHuMGDF (a truncated pegylated form) was withdrawn globally after causing neutralizing antibodies and thrombocytopenia in healthy volunteers. Not approved by FDA or EMA as a standalone agent.

Evidence & Sources

No sources recorded yet.